HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-19 July 2023

Twelfth Paediatric Oncology Strategy Forum for Medicinal Product Development of CDK4/6, CDK7 and CDK9 Inhibitors in children and adolescents, Hybrid, from 26/10/2023 to 27/10/2023

Herbal medicinal product: Melaleucae aetheroleum, Melaleucae aetheroleum, F: Assessment finalised

Minutes - Enpr-EMA Coordinating Group and networks meeting

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Arthroplasty, Replacement;Venous Thromboembolism, Date of authorisation: 30/09/2008, Revision: 40, Status: Authorised

Organisation chart: Stakeholders and Communication

Questions and answers (Q&As) on the external guidance of Policy 0070 on clinical data publication (CDP)

Opinion/decision on a Paediatric investigation plan (PIP): Rimegepant, decision type: , therapeutic area: , PIP number: P/0285/2020

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Desensitization, Immunologic;Kidney Transplantation, Date of authorisation: 25/08/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Soft Tissue Infections;Skin Diseases, Bacterial, Date of authorisation: 19/02/2015, Revision: 15, Status: Authorised